TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET

Abstract: the invention as disclosed herein relates to a bispecific antibody that comprises a 5 first variable domain that can bind an extracellular part of human epidermal growth factor receptor (egfr) and a second variable domain that can bind an extracellular part of human met proto-oncogene, receptor tyrosine kinase (cmet) for use in a method of treatment of a cancer in a subject which has received prior treatment with i) a third-generation egfr tyrosine kinase inhibitor, or ii) a chemotherapy and a tyrosine kinase 10 inhibitor or iii) a cmet tyrosine kinase inhibitor.

Inventor(s): Jeroen Jilles LAMMERTS VAN BUEREN, Gianluca LAUS, Benjamin Awori BARASA

CPC Classification: C07K16/2863 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250179193